Home › NDC Lookup › Ingredients › Carboxymethylcellulose Sodium, Glycerin,... › 00023-4491-30
REFRESH OPTIVE Advanced carboxymethylcellulose sodium, glycerin, polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops, 30 vials — NDC 00023-4491-30 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

REFRESH OPTIVE Advanced carboxymethylcellulose sodium, glycerin, polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops, 30 vials — NDC 0023-4491-30 (Billing 00023-4491-30)

by Allergan, Inc. · 30 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE

This is a package of 30 vials of REFRESH OPTIVE Advanced carboxymethylcellulose sodium, glycerin, polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops from Allergan, Inc., marketed since Jan 2013 and currently FDA-listed; retail pharmacies pay about $0.4448 per vial (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00023-4491-30
🏷️ FDA NDC (as labeled) 0023-4491-30 billing pads the labeler segment with a zero
This package
Contains30 vials Cost per ea$0.4448 NADAC Per package$13.34 / 30 vials Pack sizes2 compare ↓
Also priced by: Medicaid pays $1.27/unit — full pricing hub ↓
Main listing for product 0023-4491 · Also comes in: 5 vials 0023-4491-05
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0023-4491-30 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0023 labeler · 4491 product · 30 package
Package marketed since
Jan 15, 2013
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 0023449130 9
Medicaid fills, this package
2,368 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0023-4491-30
Product NDC 0023-4491
11-digit billing NDC 00023449130
NCPDP billing unit EA — each (per item)
RxCUI 1241471
UNII K679OBS311, PDC6A3C0OX, 6OZP39ZG8H
Application # M018
SPL Set ID ebd0839e-2e1d-4e0e-986c-19f1f5c76358
Established class (EPC) Non-Standardized Chemical Allergen
Physiologic effect Increased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical class Allergens; Glycerol
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2013-01-15
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance CARBOXYMETHYLCELLULOSE SODIUM; GLYCERIN; POLYSORBATE 80

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86209903202022
GPI class Refresh Optive Advanced PF
GCN Seq No 070905
GCN 34571
HICL code 040248
Ingredient (HICL) Carboxymethyl/Gly/Poly80/Pf
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name REFRESH OPTIVE ADVANCED DROPS
FDB brand name Refresh Optive Advanced
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 070905
  • GCN: 34571
  • GPI-14 (Medi-Span): 86209903202022
  • HICL (First Databank): 040248
  • AHFS class code: 52:92.00.00
  • RxCUI (RxNorm): 1241471
Why two NDCs? The FDA registers this code as 0023-4491-30 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-4491-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name REFRESH OPTIVE ADVANCED DROPS Ingredient Carboxymethyl/Gly/Poly80/Pf
🧪 What is this product?

Refresh Optive Advanced is an over-the-counter eye drop solution containing carboxymethylcellulose sodium, glycerin, and polysorbate 80. This product is formulated as an ophthalmic solution applied directly to the eye surface. Carboxymethylcellulose sodium and glycerin are lubricating agents commonly used to help moisturize and soothe dry eyes, while polysorbate 80 functions as a surfactant to help distribute the ingredients evenly. This is an OTC monograph product marketed under established FDA guidelines for eye lubricants.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.445 $13.34 / 30 vials
Medicaid paysCMS SDUD · 12 mo $1.27 $37.96 / 30 vials
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Sep 2022 Nov 2025 Aug 2026 $0.445 $0.407
▲ Up 4% over the last 11 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00023-4491-05 0023-4491-05 5 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE Sample — — 2013-01-15 — Active
00023-4491-30 You're viewing this Main listing 30 VIAL, SINGLE-USE in 1 CARTON / .4 mL in 1 VIAL, SINGLE-USE $0.4448 / ea $13.34 2013-01-15 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 30 vials — 30 vial, single-use in 1 carton / .4 ml in 1 vial, single-use.
How does this package differ from NDC 00023-4491-05?
Both are REFRESH OPTIVE Advanced carboxymethylcellulose sodium, glycerin, polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops — the drug itself is identical. This page's package is the 30 vials one, while NDC 00023-4491-05 is the 5 vials package.
What NDC number is used to bill for this package of REFRESH OPTIVE Advanced carboxymethylcellulose sodium, glycerin, polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
REFRESH OPTIVE Advanced 5 mg/mL; 10 mg/mL; 80 5 mg/mLthis 00023-4491-30 Allergan, 30 vials $0.445 — Availability likely —
Refresh Optive Mega-3 PF 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-3988-05 Allergan, 1 vial — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-4230-70 Allergan, 70 vials — — FDA listed —
REFRESH OPTIVE Advanced 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-4307-02 Allergan, 1 bottle — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-5773-05 Allergan, 5 vials — — FDA listed —
Refresh Digital 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-6952-02 Allergan, 1 bottle — — FDA listed —
Refresh Digital PF 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-6954-05 Allergan, 1 vial — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-7151-60 Allergan, 60 vials — — FDA listed —
Droptics Dry Eye Relief .5 g/100mL; 1 g/100mL; 80 .5 g/100mL 85211-0002-01 Droptics 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
On the market since
Jan 2013
📍
2026
Currently FDA-listed
13 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII 71DD5V995L
    A synthetic polymer derived from acrylic acid, crosslinked to form a gel-like substance. It thickens formulations, improves texture, and helps distribute active ingredients evenly in topical products like creams and gels.
  • UNII D5340Y2I9G
    Castor oil is a natural plant-based oil used in medicines as a lubricant, laxative agent, and solvent. It helps medicine ingredients dissolve or flow smoothly and can aid bowel movement in formulations designed for that purpose.
  • UNII RA96B954X6
    Erythritol is a sugar alcohol derived from fermented fruits or grains. It's used as a sweetener and bulking agent in medicines to improve taste without adding significant calories.
  • UNII 0G389FZZ9M
    Levocarnitine is an amino acid derivative that helps transport fatty acids in cells. In medications, it serves as an active nutritional component rather than a typical inactive binder or filler.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBoric acid; carbomer copolymer type A; castor oil; erythritol; levocarnitine; purified water; and sodium hydroxide (to adjust pH).

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllergan, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00023
First marketedJan 2013
Product typeHuman Otc Drug
Portfolio188 products on file

More NDCs from Allergan, Inc. labeler code 00023

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

Uses For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. May be used as a protectant against further irritation.

⏱️ Dosage and Administration 23 words ▾

Directions To open, TWIST AND PULL TAB TO REMOVE. Instill 1 or 2 drops in the affected eye(s) as needed and discard container.

⚠️ Warnings 90 words ▾

Warnings For external use only. To avoid contamination, do not touch tip of container to any surface. Do not reuse .

Once opened, discard. Do not touch unit-dose tip to eye. If solution changes color, do not use.

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 10 words ▾

Active ingredients Carboxymethylcellulose sodium 0.5% Glycerin 1% Polysorbate 80 0.5%

🧪 Inactive Ingredients 20 words ▾

Inactive ingredients Boric acid; carbomer copolymer type A; castor oil; erythritol; levocarnitine; purified water; and sodium hydroxide (to adjust pH).

🎯 Purpose 7 words ▾

Purpose Eye lubricant Eye lubricant Eye lubricant

📄 Stop Use and Ask a Doctor If 33 words ▾

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 26 words ▾

Other information Use only if single-use container is intact. Use before expiration date marked on container. Store at 59°-77°F (15°-25°C). RETAIN THIS CARTON FOR FUTURE REFERENCE.

📄 Questions or Comments 8 words ▾

Questions or comments? 1.800.678.1605 refresh eyedrops .com v1.0DFL4491

📄 Package Label / Principal Display Panel 52 words ▾

PRINCIPAL DISPLAY PANEL NDC 0023-4491-30 PRESERVATIVE-FREE Refresh OPTIVE® ADVANCED Lubricant Eye Drops with Hydrocell® T riple - A ction R elief 30 Vials 0.01 fl oz (0.4 mL) each Sterile NDC 0023-4491-30 PRESERVATIVE-FREE Refresh OPTIVE® ADVANCED Lubricant Eye Drops with Hydrocell® Triple-Action Relief 30 Vials 0.01 fl oz (0.4 mL) each Sterile

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.4K
Units reimbursed last 4 qtrs
53.2K
Gross reimbursed last 4 qtrs
$67.3K
Avg / prescription
$28.43
Avg / unit
$1.2652
Latest quarter Q1 2026
536Rx
Medicaid pays / ea
$1.2652
gross reimbursed
vs
NADAC / ea
$0.4448
acquisition cost
=
Spread
+$0.8204
+184% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
42% FFS 58% MCO
Fee-for-service · 1,006 Rx Managed care · 1,362 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 3,264 units · 56.9 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 216 units · 6.8 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 3,428 units · 50.0 per 100k residents IN Ohio: 7,916 units · 67.2 per 100k residents OH Pennsylvania: 1,290 units · 10.0 per 100k residents PA New Jersey: 30 units · 0.3 per 100k residents NJ Massachusetts: no data reported MA California: 16,728 units · 42.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 5,969 units · 302 per 100k residents NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 2,772 units · 76.6 per 100k residents CT Rhode Island: no data reported RI Arizona: 2,176 units · 29.3 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: 1,320 units · 24.6 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: 8,100 units · 564 per 100k residents HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.3564
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Hawaii 564 /100k
2 Nebraska 302 /100k
3 Connecticut 76.6 /100k
4 Ohio 67.2 /100k
5 Minnesota 56.9 /100k
6 Indiana 50.0 /100k
7 California 42.9 /100k
8 Arizona 29.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 vials this page00023-4491-30 2,368 Rx · $67,318
5 vials00023-4491-05 No Medicaid data
Drug total (last 4 qtrs): 2,368 Rx · 53,209 units · $67,318 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for REFRESH OPTIVE Advanced (this brand).

Top reported reactions

Eye Irritation125
Eye Pain69
Vision Blurred56
Dry Eye50
Cataract48
Ocular Hyperaemia34
Foreign Body Sensation In Eyes30

Age at onset

Adult18
Elderly28

Reporter sex

481 reports
Male · 19%
Female · 81%

Serious outcomes

Hospitalization36
Death5
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 48 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00023-4307-02 · Allergan, 00023-4515-30 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.